$RCEL

Woody Joseph Fralin purchased $20K of RCEL

Woody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.10 on 2026-06-03.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 5, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 5, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RCEL
Bullish
medium confidence
Mentioned
$RCEL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

The disclosure provides a concrete, dated insider buying datapoint but does not include new clinical, regulatory, or commercial developments.

02

Market read

Traders may treat this as a small sentiment input, but it is unlikely to drive a major repricing absent additional catalysts.

03

What to watch

Compare with prior insider activity and any concurrent sell transactions; also check whether the purchase price is near recent lows/highs to gauge conviction vs. timing.

Relevance 6/10Novelty 6/10Timing: After SEC Form 4 filing (filed June 5; transaction dated June 3)

Background

The article is an SEC Form 4 disclosure of an insider’s open-market purchase by a director of Avita Medical, Inc.

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

Avita Medical director Woody Joseph Fralin bought 5,000 shares in an open-market transaction on June 3, signaling insider accumulation.

Expected impact

Likely small, short-lived positive drift; not expected to materially reprice without corroborating fundamentals.

Evidence & confidence

This is an SEC Form 4 insider purchase with disclosed size and price, but no new operational/clinical/regulatory catalyst is provided.

Market effects

Limited read-across to biotech/medtech peers; insider buys are company-specific signals.

None indicated; US-listed microcap/small-cap style flow only.

None indicated.

Counterpoint

Insider buys can be routine diversification or liquidity planning; without a 10b5-1 plan and with modest dollar size, signal strength is limited.

Key entities

  • Avita Medical, Inc.

    RCEL insider transaction: director Woody Joseph Fralin purchased 5,000 shares at $4.0999 on June 3, disclosed via Form 4 filed June 5.

Related articles

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$RCELHighAI 9/10

Why is Avita Medical stock surging 20% today?

Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.

$RCELHigh

AVITA Medical, Inc. (RCEL): Results of Operations and Financial Condition

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a